EC95 of Remifentanil for Preventing Cough

• Status: Completed
• Trial end date: 2017-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigator designed this study to investigate remifentanil effect-site concentration in 95% of patients (EC95) for preventing cough after laryngomicrosurgery from propofol anesthesia.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ajou University School of Medicine
• Treatments: Anesthetics; Propofol; Remifentanil

Criteria

Inclusion Criteria:

• ASA I-II patients undergoing general anesthesia for laryngomicrosurgery

Exclusion Criteria:

• Anticipated difficult airway

• COPD, Asthma

• Recent URI (< 2 weeks)

• Severe cardiac, hepatic renal disease